Crucell veterans launch Leyden Labs with €40M to take antiviral nasal sprays toward clinic

Newly launched Leyden Labs is aiming to develop intranasal products that protect against infection by viral families that share common traits, offering broader coverage than vaccines against specific viruses or variants.

The Dutch start-up has raised €40 million ($47.6 million) in a series A round, earning the backing of GV, F-Prime Capital, Casdin Capital and veteran investor Brook Byers. The board of Leyden Laboratories B.V. also includes former Gilead Sciences Inc. (NASDAQ:GILD) Chairman John Martin...